Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33–40]

Leggi l'articolo originale

The publisher regrets the conflict of interest information provided by the authors was not included in the paper and instead the incorrect statement ‘None declared’ was published. The publisher would like to apologise for any inconvenience caused.

Lascia un commento